Maxwell Meng named Chief of Urologic Oncology

Submitted by Leslie Lingaas on November 13, 2013 at 3:47 pm

Professor Maxwell V. Meng, MD, has been named chief of urologic oncology for the department of urology–a position that oversees UCSF’s highly regarded treatment and research programs in prostate, kidney, bladder, testicular and other urologic cancers. 

In his new role, Meng will oversee strategic planning; educational programs for students, residents and fellows; clinical and basic research program assessment; and patient safety and quality of care.

"It is a great honor to lead the department’s oncology group," said Meng. "We have a talented group of individuals who are making significant contributions to providing the best care for patients with cancer, advancing new treatments, and pioneering both basic and translational research.  We are also fortunate to have colleagues with the same vision and goals in other departments, including medical and radiation oncology, radiology, and pathology."

Meng’s clinical interests include both minimally invasive and open approaches to a variety of urologic cancers, with particular emphasis on complex and advanced cases of renal cell carcinoma and testicular cancer.  He also has clinical and research experience in active surveillance for prostate cancer and new treatments for bladder and renal cancers.

Meng has been an active member of the faculty since 2003, caring for patients at the UCSF Helen Diller Family Comprehensive Cancer Center, the Veterans Administration Hospital, and San Francisco General Hospital. Since 2007, he has also directed the UCSF urologic oncology fellowship program. Meng completed much of his training at UCSF, including a urology residency and fellowships in both minimally invasive surgery and oncology.  He has held leadership positions in the American Urological Association, American College of Surgeons, Society of Urologic Oncology (SUO), and Alliance for Clinical Trials in Oncology.  Meng currently serves on the SUO fellowship committee, the scientific advisory board of the Bladder Cancer Advocacy Network, and the editorial boards of Urologic Oncology and British Journal of Urology International.

Professor Maxwell V. Meng, MD

 

Topic Area(s):